Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan + Pembrolizumab in Neoadjuvant TNBC
NCT07054242Phase 2Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer (TNBC), sponsored by Yantai Yuhuangding Hospital. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07054242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07054242.